Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

The purchases were made Tuesday through Thursday. The Occidental Petroleum buy was the first since June, suggesting Berkshire ...

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

Indian pharmaceutical giant Lupin gained US FDA approval for its generic version of Gilead Sciences' HIV drug Descovy. This win grants Lupin 180 days of shared exclusivity in the US market, a ...

Lupin is one of the first companies to receive approval for this formulation originally developed by Gilead Sciences, making ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

(CSE: BIOV) (OTCQB: BVAXF), Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), Gilead Sciences, Inc. (NASDAQ: GILD), GeoVax Labs, Inc. (NASDAQ: GOVX, GOVXW), and Vaxcyte, Inc. (NASDAQ: PCVX). The ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...

Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.